181 related articles for article (PubMed ID: 9164177)
1. Bleomycin in germ cell tumor therapy: not all regimens are created equal.
Bajorin DF; Bosl GJ
J Clin Oncol; 1997 May; 15(5):1717-9. PubMed ID: 9164177
[No Abstract] [Full Text] [Related]
2. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial.
Horwich A; Sleijfer DT; Fosså SD; Kaye SB; Oliver RT; Cullen MH; Mead GM; de Wit R; de Mulder PH; Dearnaley DP; Cook PA; Sylvester RJ; Stenning SP
J Clin Oncol; 1997 May; 15(5):1844-52. PubMed ID: 9164194
[TBL] [Abstract][Full Text] [Related]
3. Oncological outcomes of metastatic testicular cancers under centralized management through regional medical network.
Inai H; Kawai K; Kojima T; Joraku A; Shimazui T; Yamauchi A; Miyagawa T; Endo T; Fukuhara Y; Miyazaki J; Uchida K; Nishiyama H
Jpn J Clin Oncol; 2013 Dec; 43(12):1249-54. PubMed ID: 24101656
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy for good-risk germ-cell tumors.
Ryan CJ; Bajorin DF
Semin Urol Oncol; 2002 Nov; 20(4):244-50. PubMed ID: 12489057
[TBL] [Abstract][Full Text] [Related]
5. Chromosome aberrations after etoposide containing cisplatin-based chemotherapy for malignant germ-cell tumours.
Hernandez AM; Fosså SD; Brøgger A; Kat A; Skovlund E
Ann Oncol; 2000 Jul; 11(7):897-8. PubMed ID: 10997823
[No Abstract] [Full Text] [Related]
6. Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group.
de Wit R; Stoter G; Kaye SB; Sleijfer DT; Jones WG; ten Bokkel Huinink WW; Rea LA; Collette L; Sylvester R
J Clin Oncol; 1997 May; 15(5):1837-43. PubMed ID: 9164193
[TBL] [Abstract][Full Text] [Related]
7. Are 3 cycles of bleomycin, etoposide and cisplatin or 4 cycles of etoposide and cisplatin equivalent optimal regimens for patients with good risk metastatic germ cell tumors of the testis? The need for a randomized trial.
Culine S; Theodore C; Terrier-Lacombe MJ; Droz JP
J Urol; 1997 Mar; 157(3):855-8; discussion 858-9. PubMed ID: 9072585
[TBL] [Abstract][Full Text] [Related]
8. [The chemotherapy of nonseminomatous testicular tumors].
Tiuliandin SA; Bulanov AA; Titov DA; Sokolov AV; Sholokhov VN; Garin AM
Urol Nefrol (Mosk); 1996; (2):26-9. PubMed ID: 8677548
[TBL] [Abstract][Full Text] [Related]
9. Completion and toxicity of induction chemotherapy for metastatic testicular cancer: an updated evaluation of Japanese patients.
Kawai K; Ando S; Hinotsu S; Oikawa T; Sekido N; Miyanaga N; Shimazui T; Akaza H
Jpn J Clin Oncol; 2006 Jul; 36(7):425-31. PubMed ID: 16790450
[TBL] [Abstract][Full Text] [Related]
10. History of testicular cancer chemotherapy: maximizing efficacy, minimizing toxicity.
Sweeney C
Semin Urol Oncol; 2001 Aug; 19(3):170-9. PubMed ID: 11561984
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of reproductive capacity in germ cell tumor patients following treatment with cisplatin, etoposide, and bleomycin.
Stephenson WT; Poirier SM; Rubin L; Einhorn LH
J Clin Oncol; 1995 Sep; 13(9):2278-80. PubMed ID: 7545220
[TBL] [Abstract][Full Text] [Related]
12. Drug dose delivery and treatment outcome relationship in standard bleomycin, etoposide and cisplatin combination chemotherapy in nonseminomatous germ cell tumor patients.
Gutierrez-Delgado F; Titov DA; Tjulandin SA; Garin AM
Neoplasma; 1999; 46(3):190-5. PubMed ID: 10613596
[TBL] [Abstract][Full Text] [Related]
13. Intensive induction chemotherapy with CBOP/BEP in patients with poor prognosis germ cell tumors.
Christian JA; Huddart RA; Norman A; Mason M; Fossa S; Aass N; Nicholl EJ; Dearnaley DP; Horwich A
J Clin Oncol; 2003 Mar; 21(5):871-7. PubMed ID: 12610187
[TBL] [Abstract][Full Text] [Related]
14. A modified BEP protocol: reduction of hospitalization without reducing the efficacy.
Ozen H; Tekin I; Sahin A; Mahalati K; Remzi D
Urol Int; 1997; 58(1):50-4. PubMed ID: 9058522
[TBL] [Abstract][Full Text] [Related]
15. Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours.
Fizazi K; Prow DM; Do KA; Wang X; Finn L; Kim J; Daliani D; Papandreou CN; Tu SM; Millikan RE; Pagliaro LC; Logothetis CJ; Amato RJ
Br J Cancer; 2002 May; 86(10):1555-60. PubMed ID: 12085204
[TBL] [Abstract][Full Text] [Related]
16. First-line chemotherapy of disseminated germ cell tumors.
Nichols C; Kollmannsberger C
Hematol Oncol Clin North Am; 2011 Jun; 25(3):543-56, viii. PubMed ID: 21570608
[TBL] [Abstract][Full Text] [Related]
17. Carboplatin in the combination chemotherapy of non-seminomatous germ cell tumours.
Horwich A; Bliss J
Ann Oncol; 1996 Dec; 7(10):989-91. PubMed ID: 9037354
[No Abstract] [Full Text] [Related]
18. Chemotherapy of disseminated germ cell tumors.
Nichols CR
Semin Urol Oncol; 2001 Aug; 19(3):157-64. PubMed ID: 11561982
[TBL] [Abstract][Full Text] [Related]
19. Reassessment of 4-Cycle Etoposide and Cisplatin as the Standard of Care for Good-Risk Metastatic Germ Cell Tumors.
Fein DE; Paulus JK; Mathew P
JAMA Oncol; 2018 Dec; 4(12):1661-1662. PubMed ID: 30325997
[No Abstract] [Full Text] [Related]
20. Adjuvant chemotherapy for testicular cancer.
Xiao H; Sheinfeld J; Motzer RJ
Surg Oncol Clin N Am; 1997 Oct; 6(4):863-78. PubMed ID: 9309098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
